Recent proteomics studies reveal brain cells don't just recycle damaged components randomly. They target specific organelles, synaptic proteins, and signaling complexes through dedicated receptor systems. Understanding which cargoes get degraded explains why autophagy dysfunction shows up in such different ways across neurological diseases. A Nature Neuroscience review from researchers across Columbia, MIT, and the University of Tokyo synthesizes the latest findings on how neurons and brain support cells use autophagy to maintain function. The paper maps out what gets degraded, where it happens, and what goes wrong in disease. Autophagy is your cell's recycling system. Double-membraned structures called autophagosomes wrap around damaged proteins or worn-out organelles, then fuse with lysosomes that break everything down into reusable building blocks. The brain depends on this process more than most organs. Why? Neurons don't divide. A brain cell you're born with has to last your entire life. Without the ability to dilute damage through cell division, neurons rely heavily on quality control systems to remove dysfunctional components before they accumulate. The key insight from recent research: autophagy isn't one generic cleanup program. It's dozens of specialized pathways that target specific cellular structures in specific locations. What gets targeted: • Endoplasmic reticulum fragments in axons • Mitochondria with damaged DNA • Golgi apparatus components • Synaptic vesicle proteins • Signaling complexes that regulate neurotransmitter release Each target requires its own recognition system. Receptor proteins act as tags that say "degrade this but not that." One receptor targets mitochondria. Another targets ER. A third targets protein aggregates. The specificity determines which cellular functions stay intact and which get recycled. In axons, the long cables that transmit signals between neurons, autophagy primarily targets ER. This makes sense because ER in axons helps regulate calcium and protein folding far from the cell body. When axonal ER autophagy fails, calcium handling breaks down and proteins misfold. At synapses, where neurons communicate, autophagy regulates the machinery that releases neurotransmitters. Specifically, it controls levels of proteins that package neurotransmitters into vesicles and proteins that regulate how readily those vesicles get released. Too much autophagy at synapses reduces neurotransmitter release. Too little allows damaged components to accumulate. The balance determines synaptic strength, which translates directly to learning, memory, and cognitive function. Mitochondria get targeted through a different pathway. Damaged mitochondria with broken DNA or compromised energy production get tagged with ubiquitin, a small protein that acts as a "remove me" signal. Receptors recognize the tag and initiate autophagy. In Parkinson's disease, mutations in PINK1 and Parkin, two proteins that tag damaged mitochondria, prevent removal. Dysfunctional mitochondria accumulate, generating oxidative stress and eventually killing dopamine neurons in the substantia nigra. In Alzheimer's disease, a different pattern emerges. Autophagy initiation appears normal, but the fusion between autophagosomes and lysosomes gets disrupted. Autophagosomes form, capture cargo, but can't complete degradation. They pile up in neurons filled with undigested material. The review identifies genetic evidence that connects autophagy directly to brain disease. Mutations in core autophagy genes cause severe neurodevelopmental disorders. Children born with these mutations develop progressive neurodegeneration starting in infancy. Diseases linked to autophagy gene mutations: • Vici syndrome (EPG5 mutations) • Childhood-onset neurodegeneration (WDR45 mutations) • Hereditary spastic paraplegia (multiple autophagy gene mutations) • Early-onset Parkinson's (PINK1, Parkin mutations) These genetic cases prove autophagy is essential for brain development and maintenance. When the pathway is severely disrupted from birth, the nervous system can't develop normally. When it declines gradually with age, neurodegenerative disease follows. Brain support cells, called glia, also use autophagy but in different ways than neurons. Astrocytes, which support neuron metabolism and regulate the brain environment, use autophagy to control inflammation. When astrocyte autophagy fails, inflammatory signaling increases. Microglia, the brain's immune cells, use autophagy to clear debris and dead cells. Microglial autophagy dysfunction leads to accumulation of toxic protein aggregates that should have been removed, contributing to neurodegeneration. The spatial organization matters. In neurons, autophagosomes typically form in axons and dendrites but must travel back to the cell body to fuse with lysosomes. Lysosomes concentrate near the nucleus. If transport fails, cargo gets trapped far from degradation machinery. This creates vulnerability. Neurons with extremely long axons are particularly sensitive to transport disruptions. Motor neurons that stretch from spinal cord to muscles can be over three feet long. A traffic jam anywhere along that distance prevents autophagy completion. Amyotrophic lateral sclerosis (ALS), which kills motor neurons, shows evidence of both autophagy induction and impaired autophagosome transport. The pathway activates in response to stress, but completion fails because cargo can't reach lysosomes. Age is the biggest risk factor for most neurodegenerative diseases, and autophagy declines with age. Multiple steps in the pathway become less efficient: initiation slows, lysosome function decreases, and autophagosome-lysosome fusion becomes impaired. The decline creates a feedback loop. Autophagy removes damaged mitochondria. When autophagy declines, damaged mitochondria accumulate. Damaged mitochondria generate reactive oxygen species that damage more cellular components, including autophagy machinery. The cycle accelerates. Current therapeutic approaches focus on boosting autophagy through mTOR inhibition (rapamycin), enhancing lysosome function, or activating specific autophagy receptors. Boosting autophagy system-wide could help clear protein aggregates and damaged organelles. But if lysosome capacity can't keep up with increased autophagosome formation, the strategy backfires. More autophagosomes without more degradation capacity leads to traffic jams. Targeting specific receptors offers more precision. Enhancing mitochondrial autophagy selectively could help Parkinson's disease without affecting other autophagy types. Modulating synaptic autophagy could influence neurotransmitter release in psychiatric conditions. The review emphasizes that context matters. The same autophagy pathway produces opposite effects depending on cell type, subcellular location, disease stage, and which specific cargo is being degraded. One-size-fits-all approaches are unlikely to work. Understanding selective autophagy reveals why the pathway is both protective and, when dysregulated, damaging. It's not just about how much autophagy occurs but what gets degraded, where, and when. The next generation of therapeutics will likely need to target specific autophagy subtypes rather than the general pathway. That requires understanding the receptor systems, the transport mechanisms, and the disease-specific patterns of dysfunction. For now, the evidence points to autophagy as central to brain aging and neurodegeneration. Keeping the pathway functional appears critical for maintaining cognitive function into late life. How to do that pharmacologically remains an open question, but the molecular targets are becoming clearer.